Purchase Order N3239825PA019
Award Date
4/14/25
Potential Completion Date
4/13/26
Potential Value
$129K
Federal Agency
Bureau of Medicine and Surgery
Awardee
HDT Bio Corp
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
3590 - Miscellaneous Service And Trade Equipment
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Peru
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...
HDT Bio Corp. was awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein bound to lipid inorganic nanoparticle formulation, through a Phase I clinical trial. The contract was awarded under the 2020 NIAID Omnibus Broad Agency Announcement seeking proposals to develop medical countermeasures including vaccines,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.5 million firm fixed price definitive contract to HDT Bio Corp. to develop an adaptable RNA-based antibody platform for protection against contemporary and emerging human enteroviruses. The three year contract will support HDT Bio Corp.'s work through June 2025 to create a platform that utilizes RNA-based antibodies to provide protection against various...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $627,627.92 definitive contract to Nature's Toolbox Inc., doing business as Biotechnology, a subsidiary of Nature's Toolbox, Inc., for research and development of a novel, rapidly deployable RNA vaccine production platform under AOI #21 Vaccines on Demand. The firm fixed price contract will be performed in Mexico over a period of approximately two years, from April 2023 through...
This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...
This federal contract award to Research And Diagnostic Systems, Inc. (R&D Systems), a subsidiary of Bio-Techne Corporation, was made by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The $10,242.30 firm fixed-price purchase order is for the delivery of antibodies and proteins to support biomedical research, including studies related to COVID-19 and other infectious diseases. R&D Systems is a...
<p>This is a firm-fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Grapheno, LLC, a small business, under the SBIR Phase I program. The contract is for the development of a "HALOVAX: Clay Nanotube-Based Vaccine Delivery Patches for the Sustained Release of an HIV Vaccine" as medical research and development. The contract has a ceiling value of $249,978.59 and a period of performance ending on August 26, 2025.</p>
This is a $37,000 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Protein Sciences Corp, a for-profit manufacturer, to provide purified recombinant proteins. The contract has no set-aside designation. Protein Sciences Corp has received multiple federal contract awards from HHS's Office of the Assistant Secretary for Preparedness and Response...
This is a delivery order under a larger Therapeutics Against Infectious Diseases Phase 1 indefinite delivery/indefinite quantity (IDIQ) contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The $117,283 order provides base task funding to the prime contractor, Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for a Phase 1 clinical trial unit supporting the...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...